Breakthrough in Reversing Immunotherapy-Induced Diabetes
A UCLA study has found that a common autoimmune drug may help reverse immunotherapy-induced diabetes.
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center identified a potential new strategy to prevent and reverse immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy.
The study, published in JCI Insight, reveals that JAK inhibitors, already FDA-approved for conditions like psoriasis and arthritis, can stop the autoimmune attack on insulin-producing cells in the pancreas and even reverse the damage in preclinical models.
The study identifies a new group of immune cells involved in the development of immune checkpoint inhibitor–induced type 1 diabetes, offering new hope for patients.
Author's summary: UCLA researchers find autoimmune drug may reverse immunotherapy-induced diabetes.